Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

Peihua Lu, Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Meiwei Gong, Hui Wang, Jiaqi Chen, Hongxing Liu, Min Xiong, Ying Liu, Lin Wang

Blood blood.2024024861.

https://doi.org/10.1182/blood.2024024861

Published: 2024

Includes: Supplemental data

Journal Articles

CD7-Targeted CAR-T Cell Therapy Shows Promising Efficacy and Safety in Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: Phase I Clinical Trial

Junfang Yang, Xian Zhang, Jingjing Li, Liyuan Qiu, Lin Wang, Peihua Lu

Blood (2024) 144 (Supplement 1): 2075.

https://doi.org/10.1182/blood-2024-196853

Published: 2024

Journal Articles

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

Xian Zhang, Qinglong Wang, Ying Liu, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 6883.

https://doi.org/10.1182/blood-2023-185361

Published: 2023

Journal Articles

CD7 CAR-T Therapy Followed By a Second Transplant for T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients Who Relapsed after a Prior Transplant

Xingyu Cao, Jianping Zhang, Yue Lu, Yanli Zhao, Deyan Liu, Min Xiong, Zhijie Wei, Jiarui Zhou, Xian Zhang, Junfang Yang, Hongxing Liu, Peihua Lu

Blood (2023) 142 (Supplement 1): 2155.

https://doi.org/10.1182/blood-2023-186030

Published: 2023

Journal Articles

Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Hongxing Liu, Sr., Min Xiong, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 218.

https://doi.org/10.1182/blood-2023-179086

Published: 2023

Journal Articles

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

Xian Zhang, Lin Wang, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2023-185271

Published: 2023

Journal Articles

A Parallel Comparison of the Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for Refractory and Relapsed T-ALL/Lbl Patients Who Achieved Complete Remission with CD7 CAR-T Versus Patients Who Achieved First Complete Remission with Chemotherapy before Transplantation

Xingyu Cao, Jianping Zhang, Yue Lu, Yanli Zhao, Deyan Liu, Min Xiong, Ruijuan Sun, Zhijie Wei, Jiarui Zhou, Xian Zhang, Junfang Yang, Hongxing Liu, Sr., Peihua Lu

Blood (2023) 142 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2023-185696

Published: 2023

Journal Articles

Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy

Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Jianqiang Li, Peihua Lu

Blood (2022) 140 (Supplement 1): 2369–2370.

https://doi.org/10.1182/blood-2022-158878

Published: 2022

Journal Articles

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Xing-yu Cao, Jian-Ping Zhang, Yan-Li Zhao, Min Xiong, Jiarui Zhou, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Xian Zhang, Junfang Yang, Peihua Lu

Blood (2022) 140 (Supplement 1): 4802–4803.

https://doi.org/10.1182/blood-2022-166993

Published: 2022

Journal Articles

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Xian Zhang, Yali Zhou, Junfang Yang, Jingjing Li, Liyuan Qiu, Wengang Ge, Bo Pei, Jie Chen, Lu Han, Jiangtao Ren, Peihua Lu

Blood (2022) 140 (Supplement 1): 4566–4567.

https://doi.org/10.1182/blood-2022-165733

Published: 2022

Journal Articles

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

Peihua Lu, Ying Liu, Junfang Yang, Xian Zhang, Xiao Yang, Hui Wang, Lin Wang, Qinglong Wang, David Jin, Jianqiang Li, Xiaojun Huang

Blood (2022) 140 (4): 321–334.

https://doi.org/10.1182/blood.2021014498

Published: 2022

Includes: Supplemental data

Journal Articles

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy

Xian Zhang, Gailing Zhang, Wenqian Li, Yang Zhang, Tong Wang, Junfang Yang, Jingjing Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 3828.

https://doi.org/10.1182/blood-2021-149809

Published: 2021

Journal Articles

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Junfang Yang, Xian Zhang, Ying Liu, Xiao Yang, Hui Wang, Lin Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 473.

https://doi.org/10.1182/blood-2021-147667

Published: 2021

Journal Articles

Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia

Xian Zhang, Gailing Zhang, Wenqian Li, Liyuan Qiu, Dongchu Wang, Junfang Yang, Jingjing Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 2820.

https://doi.org/10.1182/blood-2021-149978

Published: 2021

Journal Articles

Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1830.

https://doi.org/10.1182/blood-2021-150037

Published: 2021

Journal Articles

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

Xian Zhang, Junfang Yang, Jingjing Li, Yanze Shi, Yunchao Su, Ying Liu, Min Ba, Yan Wu, Wenqian Li, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2021-146425

Published: 2021

Journal Articles

A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)

Junfang Yang, Xiao Yang, Ying Liu, Qinglong Wang, Hui Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 652.

https://doi.org/10.1182/blood-2021-147754

Published: 2021

Journal Articles

A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Jiasheng Wang, Yue Liu, Junfang Yang, Jingjing Li, Gailing Zhang, MD, Yanze Shi, Jiujiang He, Dan Song, Wenqian Li, Shulian Xia, Min Zhang, Zhixiao Zhou, Lemei Jia, Hongli Zheng, Xin Lin, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-136833

Published: 2020

Journal Articles

Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Junfang Yang, Pengfei Jiang, Xian Zhang, MD, Jingjing Li, Yan Wu, Li Xu, Yunchao Su, Xiaona Hu, Xiaoyan Zhao, Qi Dong, Songbai Cai, Zhenguang Wang, Yuezhang Chen, Xun Ye, Jiaping He, Nanjing Lin, Wei Cao, Martina Sersch, MD PhD, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136866

Published: 2020

Journal Articles

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Xian Zhang, MD, Junfang Yang, Wenqian Li, Gailing Zhang, MD, Yunchao Su, Yanze Shi, Dan Song, Min Zhang, Jiujiang He, Li Xu, Liyuan Qiu, Xin-An Lu, Fei Wu, Jianqiang Li, PhD, Dandan Chen, Xiangqun Li, Ziyu Li, Jingjing Li, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-137299

Published: 2020

NARROW

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

CD7-Targeted CAR-T Cell Therapy Shows Promising Efficacy and Safety in Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: Phase I Clinical Trial

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

CD7 CAR-T Therapy Followed By a Second Transplant for T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients Who Relapsed after a Prior Transplant

Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

A Parallel Comparison of the Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for Refractory and Relapsed T-ALL/Lbl Patients Who Achieved Complete Remission with CD7 CAR-T Versus Patients Who Achieved First Complete Remission with Chemotherapy before Transplantation

Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia

Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)

A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only